Part VI:
Summary of the risk management plan by product

Summary of risk management plan for Acido Zoledronico Galenica Senese (Zoledronic Acid)

This is a summary of the risk management plan (RMP) for Acido Zoledronico Galenica Senese. The RMP details important risks of Acido Zoledronico Galenica Senese, how these risks can be minimised, and how more information will be obtained about Acido Zoledronico Galenica Senese risks and uncertainties (missing information).

Acido Zoledronico Galenica Senese summary of product charactetistics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Acido Zoledronico Galenica Senese should be used.

I. The medicine and what it is used for

Acido Zoledronico Galenica Senese is authorized for the prevention of events related to the skeletal system (pathological fractures, vertebral crushing, radiotherapy or bone surgery, neoplastic hypercalcaemia) in adult patients with advanced malignant tumors affecting the bone and for the treatment of adult patients with neoplastic hypercalcaemia (TIH).

It contains zoledronic acid as the active substance and it is given by intravenous route.

II. Risks associated with the medicine and activities to minimize or further characterize the risks

Important risks of Acido Zoledronico Galenica Senese, together with measures to minimise such risks and the proposed studies for learning more about Acido Zoledronico Galenica Senese risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet, SmPC, patient reminder card addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In the case of Acido Zoledronico Galenica Senese, these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate actions can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Acido Zoledronico Galenica Senese are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Acido Zoledronico Galenica Senese. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table SVIII.1: Summary of safety concerns

Important identified risks	- Renal function impairment/dysfunction - Osteonecrosis of the jaw - Hypocalcaemia - Interstitial lung disease - Anaphylaxis - Acute phase reactions - Atrial fibrillation -Interaction with anti-angiogenic drugs
Important potential risks	- Atypical femoral fractures - Cardiac arrhythmias - Cerebrovascular AEs - Focal segmental Glomerulosclerosis -Fracture healing impairment - Off-label use in osteogenesis-imperfecta -Medication errors -Interaction with products that can significantly affect renal function -Teratogenicity
Missing information	- Races other than Caucasian - Fertility, Pregnancy and Lactation - Patients with several renal impairment - Patients with hepatic insufficiency

II.B Summary of important risks

According the reference medicinal product, the important identified risks are:

- Renal insufficiency
- Osteonecrosis of the jaw
- Hypocalcaemia
- Interstitial lung disease
- Anaphylaxis
- Acute phase reactions
- Atypical femoral fractures
- Cardiac arrhythmias
- Cerebrovascular AES
- Focal Segmental Glomerulosclerosis
- Fracture healing impairement
- Off label use in osteogenesis imperfecta
- Atrial fibrillation
- Interaction with anti-angiogenic drugs
- Medication errors
- Interaction with products that can significantly affect renal function

According the Guidance on the format of the risk management paln (RMP) in the EU – in integrated format Rev 2, the following statement is reported:

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Acido Zoledronico Galenica Senese.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Acido Zoledronico Galenica Senese.